Table 2.

Treatment characteristics.

	No. of Patients (n = 40)
Neoadjuvant chemotherapy
Number of cycles—no. (%)
0	0 (0)
3	13 (33)
4	22 (55)
5 or more	5 (12)
Cytoreductive surgery
HIPEC agent—no. (%)
Carboplatin	40 (100)
HIPEC duration—no. (%)
Carboplatin 60 min	10 (25)
Carboplatin 90 min	30 (75)
Complete cytoreduction1—no. (%)
CC-0	38 (95)
CC-1	2 (5)
Median peritoneal cancer index (range)	13 (5–34)
Peritoneal cancer index—no. (%)
0–15	25 (63)
16 or more	15 (37)
Median blood loss (range)—mL	1000 (300–4000)
Median duration of procedure (range)—min	475 (300–900)
Supracolic omentectomy	31 (78)
Peritonectomy	26 (65)
Partial hepatectomy	2 (5)
Splenectomy	6 (15)
Bowel resection—no. (%)	20 (50)
Small bowel resection	2 (5)
Colon resection	20 (50)
Partial gastrectomy	2 (5)
Bowel resection with ileostomy	4 (10)
Bowel resection with colostomy	0 (0)
Rectal anastomosis	16 (40)
Paraaortic lymph node dissection	10 (25)
Adjuvant chemotherapy
Number of cycles—no. (%)
0	1 (3)
1–2	4 (10)
3	35 (87)
Total number of cycles—no. (%)
3–5	2 (5)
6–7	33 (83)
8 or more	5 (12)

CC-0, no visible residual tumor; CC-1, residual disease < 2.5 mm.